Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

308.05 -2.75 (-0.88%)
Streaming Delayed Price Updated: 3:13 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Examining the Quality Attributes of UNITED THERAPEUTICS CORP (NASDAQ:UTHR).
A fundamental analysis of (NASDAQ:UTHR): Why UNITED THERAPEUTICS CORP (NASDAQ:UTHR) qualifies as a quality stock. 
Via Chartmill
3 Big Reasons to Love United Therapeutics (UTHR)
What a brutal six months it’s been for United Therapeutics. The stock has dropped 23.1% and now trades at $308, rattling many shareholders. This might have investors contemplating their next move. 
Via StockStory
Unpacking Q1 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Vertex... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Following Peter Lynch’s approach: Does UNITED THERAPEUTICS CORP (NASDAQ:UTHR) fit the bill?
Let’s dive into UNITED THERAPEUTICS CORP (NASDAQ:UTHR) using Peter Lynch’s key investing principles, from earnings growth and debt levels to long-term scalability and valuation. 
Via Chartmill
Earnings Scheduled For April 30, 2025
Via Benzinga
The Top 3 Stock Picks at the World’s Greatest Hedge Fund
See which three stocks the world's most successful hedge fund, which generated returns of +30% for decades, had the biggest stakes in at the end of 2024. 
Via MarketBeat
Topics Regulatory Compliance
Exposures Legal Regulatory
UNITED THERAPEUTICS CORP (NASDAQ:UTHR): A Potential Undervalued Opportunity
UNITED THERAPEUTICS CORP (NASDAQ:UTHR): A Potential Undervalued Opportunity 
Via Chartmill
1 Value Stock Worth Investigating and 2 to Brush Off
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few... 
Via StockStory
United Therapeutics (NASDAQ:UTHR) Reports Bullish Q1
Biotechnology company United Therapeutics (NASDAQ:UTHR) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 17.2% year on year to $794.4 million. Its GAAP profit of... 
Via StockStory
United Therapeutics Corporation Reports First Quarter 2025 Financial Results
From United Therapeutics Corporation
Via Business Wire
United Therapeutics (UTHR) To Report Earnings Tomorrow: Here Is What To Expect
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow morning. Here’s what to look for. 
Via StockStory
Topics Government World Trade
Exposures Political Tariff
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
Via Benzinga
This United Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday
Via Benzinga
Demystifying United Therapeutics: Insights From 4 Analyst Reviews
Via Benzinga
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025
From United Therapeutics Corporation
Via Business Wire
How does UNITED THERAPEUTICS CORP (NASDAQ:UTHR) stack up against Peter Lynch’s investment principles?
Peter Lynch’s approach focused on identifying undervalued growth stocks with simple, scalable businesses. We examine whether UNITED THERAPEUTICS CORP (NASDAQ:UTHR) fits the characteristics of a... 
Via Chartmill
2 of Wall Street’s Favorite Stocks to Target This Week and 1 to Question
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Spotting Winners: United Therapeutics (NASDAQ:UTHR) And Therapeutics Stocks In Q4
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with United... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Quality Investors May Find UNITED THERAPEUTICS CORP (NASDAQ:UTHR) Attractive.
A fundamental analysis of (NASDAQ:UTHR): Is UNITED THERAPEUTICS CORP (NASDAQ:UTHR) a Strong Candidate for Quality Investing? 
Via Chartmill
United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the International Society for Heart and Lung Transplantation 45th Annual Meeting and Scientific Sessions
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Named to ‘100 Best Companies to Work For’ in 2025 by Fortune Media and Great Place to Work
From United Therapeutics Corporation
Via Business Wire
3 Reasons Investors Watch United Therapeutics (UTHR)
Over the last six months, United Therapeutics shares have sunk to $308.27, producing a disappointing 14% loss - worse than the S&P 500’s 1.4% drop. This was partly due to its softer quarterly results... 
Via StockStory
Topics Stocks
Exposures US Equities
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Healthcare Stocks with Solid Fundamentals and 1 to Brush Off
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Evaluating UNITED THERAPEUTICS CORP (NASDAQ:UTHR) using Peter Lynch’s legendary strategy
With a strategy that emphasized steady earnings growth and a strong market position, Peter Lynch sought out long-term winners. We put UNITED THERAPEUTICS CORP (NASDAQ:UTHR) to the test against his... 
Via Chartmill
2 Value Stocks on Our Watchlist and 1 to Ignore
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025
From United Therapeutics Corporation
Via Business Wire
Why United Therapeutics (UTHR) Stock Is Down Today
Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 10.9% in the afternoon session after the company reported disappointing fourth-quarter results: EPS missed analysts' expectations,... 
Via StockStory
United Therapeutics (NASDAQ:UTHR) Reports Q4 In Line With Expectations
Biotechnology company United Therapeutics (NASDAQ:UTHR) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 19.7% year on year to $735.9 million. Its GAAP profit of $6.19 per share was... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.